Cellosaurus logo
expasy logo

Cellosaurus KMH-2 (CVCL_S641)

[Text version]
Cell line name KMH-2
Synonyms KMHDASH2; KMH2
Accession CVCL_S641
Resource Identification Initiative To cite this cell line use: KMH-2 (RRID:CVCL_S641)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: 58 hours (PubMed=11686581).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
Sequence variations
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; DepMap).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.62
Native American0.61
East Asian, North81.17
East Asian, South14.36
South Asian0
European, North0.83
European, South1.41
Disease Thyroid gland anaplastic carcinoma (NCIt: C3878)
Anaplastic thyroid carcinoma (ORDO: Orphanet_142)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 71Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=30737244

Markers:
AmelogeninX,Y
CSF1PO10,11
D3S135815
D5S81812,13
D7S82011
D8S117913
D13S3179
D16S5399,12
D18S5117
D21S1130,32.2
FGA20,22
TH019
TPOX8,11
vWA14,15

Run an STR similarity search on this cell line
Publications

PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7
Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I., Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.
Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines.
Biomed. Pharmacother. 55:466-474(2001)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) CLS; 305142
JCRB; JCRB1066
JCRB; NIHS0268 - Discontinued
Cell line databases/resources CLO; CLO_0037155
cancercelllines; CVCL_S641
CCRID; 3101HUMSCSP551
Cell_Model_Passport; SIDM00619
Cosmic-CLP; 1298167
DepMap; ACH-002397
LINCS_LDP; LCL-1684
Biological sample resources BioSample; SAMN03472496
Chemistry resources GDSC; 1298167
PharmacoDB; KMH2_755_2019
Encyclopedic resources Wikidata; Q54900116
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827259
GEO; GSM1669989
Polymorphism and mutation databases Cosmic; 2054094
Progenetix; CVCL_S641
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation03-Feb-2014
Last entry update05-Oct-2023
Version number31